Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Lancet publication 'strong validation' Genfit's NIS4, says H.C. Wainwright » 12:10
08/05/20
08/05
12:10
08/05/20
12:10
GNFT

Genfit

$5.20 /

+ (+0.00%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GNFT Genfit
$5.20 /

+ (+0.00%)

GNFT Genfit
$5.20 /

+ (+0.00%)

07/23/20 H.C. Wainwright
Genfit price target lowered to $8 from $11 at H.C. Wainwright
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
GNFT Genfit
$5.20 /

+ (+0.00%)

Hot Stocks
Genfit announces publication of NIS4 technology in Lancet » 12:07
08/05/20
08/05
12:07
08/05/20
12:07
GNFT

Genfit

$5.20 /

+ (+0.00%)

Genfit earlier today…

Genfit earlier today announced that pivotal data describing the derivation and validation of NIS4 has been accepted for publication by The Lancet Gastroenterology & Hepatology. NIS4 is the company's non-invasive, blood-based diagnostic technology, developed to identify patients with nonalcoholic steatohepatitis and significant to advanced fibrosis. Suneil Hosmane, Head of Global Diagnostics at Genfit commented: "This publication represents a milestone achievement for our NIS4(TM) technology. The data presented in The Lancet Gastroenterology and Hepatology showcases not only the robust and consistent performance of NIS4 to identify at-risk NASH, but also the improved performance of NIS4 relative to other technologies including commonly used liver fibrosis tests." Genfit intends to license NIS4 technology to a diagnostic partner to enable the development and projected launch of a clinical diagnostic test powered by NIS4 in the second half of 2020. Genfit added that it continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic version of NIS4 in both the U.S. and European markets.

ShowHide Related Items >><<
GNFT Genfit
$5.20 /

+ (+0.00%)

GNFT Genfit
$5.20 /

+ (+0.00%)

07/23/20 H.C. Wainwright
Genfit price target lowered to $8 from $11 at H.C. Wainwright
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
GNFT Genfit
$5.20 /

+ (+0.00%)

Over a week ago
Recommendations
Genfit price target lowered to $8 from $11 at H.C. Wainwright » 10:51
07/23/20
07/23
10:51
07/23/20
10:51
GNFT

Genfit

$5.65 /

+0.25 (+4.63%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce lowered the firm's price target on Genfit to $8 from $11 and keeps a Neutral rating on the shares after the company announced its decision to discontinue the Phase 3 RESOLVE-IT trial of elafibranor for the treatment of nonalcoholic steatohepatitis. Though not guided by management, the analyst anticipates Genfit to initiate a Phase 3 pivotal trial of elafibranor for primary biliary cholangitis by year-end, noting elafibranor previously met the primary endpoint of serum alkaline phosphatase. He maintains a Neutral rating on Genfit pending a complete picture of its new clinical strategy.

ShowHide Related Items >><<
GNFT Genfit
$5.65 /

+0.25 (+4.63%)

GNFT Genfit
$5.65 /

+0.25 (+4.63%)

07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
GNFT Genfit
$5.65 /

+0.25 (+4.63%)

GNFT Genfit
$5.65 /

+0.25 (+4.63%)

Upgrade
Fly Intel: Top five analyst upgrades » 10:14
07/23/20
07/23
10:14
07/23/20
10:14
TSLA

Tesla

$1,606.20 /

+16.2 (+1.02%)

, TXN

Texas Instruments

$131.40 /

-1.12 (-0.85%)

, APA

Apache

$14.41 /

-0.1 (-0.69%)

, MRO

Marathon Oil

$5.78 /

-0.01 (-0.17%)

, GNFT

Genfit

$5.50 /

+0.1 (+1.85%)

, SUM

Summit Materials

$17.90 /

+0.19 (+1.07%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Market Perform from Underperform at Cowen. 2. Texas Instruments (TXN) upgraded to Buy from Hold at DZ Bank. 3. Apache (APA) and Marathon Oil (MRO) upgraded to Overweight from Neutral at JPMorgan. 4. Genfit (GNFT) upgraded to Buy from Hold at Stifel with analyst Derek Archila saying the move to discontinue its nonalcoholic steatohepatitis program to focus on elafibranor's Phase 3 in primary biliary cholangitis where it has "solid proof-of-concept data and can benefit from orphan pricing would be a positive." 5. Summit Materials (SUM) upgraded to Buy from Hold at Loop Capital with analyst Garik Shmois saying he thinks the pullback yesterday disconnected with what was an exceptionally strong quarter and very solid Q3 outlook and sees the risk/reward as too favorable to ignore. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
TXN Texas Instruments
$131.40 /

-1.12 (-0.85%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

SUM Summit Materials
$17.90 /

+0.19 (+1.07%)

MRO Marathon Oil
$5.78 /

-0.01 (-0.17%)

GNFT Genfit
$5.50 /

+0.1 (+1.85%)

APA Apache
$14.41 /

-0.1 (-0.69%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

07/23/20 Oppenheimer
Tesla price target raised to $2,209 from $968 at Oppenheimer
07/23/20 Wedbush
Tesla price target raised to $1,800, bull case to $2,500 at Wedbush
07/23/20 Morgan Stanley
Morgan Stanley says Tesla bears 'really have to nit pick' to be negative on Q2
07/23/20 JPMorgan
Most of Tesla Q2 beat driven by regulatory credit sales, says JPMorgan
TXN Texas Instruments
$131.40 /

-1.12 (-0.85%)

07/23/20 DZ Bank
Texas Instruments upgraded to Buy from Hold at DZ Bank
07/22/20 Credit Suisse
Texas Instruments price target raised to $155 from $140 at Credit Suisse
07/22/20 Susquehanna
Texas Instruments price target raised to $165 from $155 at Susquehanna
07/22/20 Stifel
Texas Instruments price target raised to $140 from $125 at Stifel
APA Apache
$14.41 /

-0.1 (-0.69%)

07/23/20 JPMorgan
Apache upgraded on benefits from potential federal moratorium at JPMorgan
07/23/20 JPMorgan
Apache upgraded to Overweight from Neutral at JPMorgan
07/20/20 Raymond James
Apache upgraded to Outperform from Market Perform at Raymond James
07/20/20 Raymond James
Apache upgraded to Outperform from Market Perform at Raymond James
MRO Marathon Oil
$5.78 /

-0.01 (-0.17%)

07/23/20 JPMorgan
Marathon Oil upgraded to Overweight with 38% upside potential at JPMorgan
07/23/20 JPMorgan
Marathon Oil upgraded to Overweight from Neutral at JPMorgan
06/25/20 Wells Fargo
Marathon Oil downgraded to Equal Weight from Overweight at Wells Fargo
06/25/20 Wells Fargo
Marathon Oil downgraded to Equal Weight from Overweight at Wells Fargo
GNFT Genfit
$5.50 /

+0.1 (+1.85%)

07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
SUM Summit Materials
$17.90 /

+0.19 (+1.07%)

07/23/20 Loop Capital
Summit Materials upgraded to Buy from Hold at Loop Capital
07/23/20 Loop Capital
Summit Materials upgraded to Buy from Hold at Loop Capital
07/23/20 Deutsche Bank
Summit Materials should be bought on earnings selloff, says Deutsche Bank
07/09/20 Truist
Summit Materials upgraded to Buy from Hold at SunTrust
TXN Texas Instruments
$131.40 /

-1.12 (-0.85%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

SUM Summit Materials
$17.90 /

+0.19 (+1.07%)

MRO Marathon Oil
$5.78 /

-0.01 (-0.17%)

APA Apache
$14.41 /

-0.1 (-0.69%)

  • 14
    Feb
TXN Texas Instruments
$131.40 /

-1.12 (-0.85%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

MRO Marathon Oil
$5.78 /

-0.01 (-0.17%)

GNFT Genfit
$5.50 /

+0.1 (+1.85%)

APA Apache
$14.41 /

-0.1 (-0.69%)

TXN Texas Instruments
$131.40 /

-1.12 (-0.85%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

MRO Marathon Oil
$5.78 /

-0.01 (-0.17%)

GNFT Genfit
$5.50 /

+0.1 (+1.85%)

APA Apache
$14.41 /

-0.1 (-0.69%)

TXN Texas Instruments
$131.40 /

-1.12 (-0.85%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

MRO Marathon Oil
$5.78 /

-0.01 (-0.17%)

APA Apache
$14.41 /

-0.1 (-0.69%)

TSLA Tesla
$1,606.20 /

+16.2 (+1.02%)

Upgrade
Genfit upgraded to Buy from Hold at Stifel » 04:51
07/23/20
07/23
04:51
07/23/20
04:51
GNFT

Genfit

$5.40 /

-0.18 (-3.23%)

Stifel analyst Derek…

Stifel analyst Derek Archila upgraded Genfit to Buy from Hold with an unchanged price target of EUR 11. The move to discontinue its nonalcoholic steatohepatitis program to focus on elafibranor's Phase 3 in primary biliary cholangitis where it has "solid proof-of-concept data and can benefit from orphan pricing would be a positive," Archila tells investors in a research note. With shares trading below cash of EUR 7 per share, the analyst thinks the risk/reward is favorable, and he believes the company should have enough cash runway to get to a Phase 3 PBC read out.

ShowHide Related Items >><<
GNFT Genfit
$5.40 /

-0.18 (-3.23%)

GNFT Genfit
$5.40 /

-0.18 (-3.23%)

06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
GNFT Genfit
$5.40 /

-0.18 (-3.23%)

GNFT Genfit
$5.40 /

-0.18 (-3.23%)

Hot Stocks
Genfit discontinues Phase 3 elafibranor trial in steatohepatitis, fibrosis » 04:48
07/23/20
07/23
04:48
07/23/20
04:48
GNFT

Genfit

$5.40 /

-0.18 (-3.23%)

Genfit announced the…

Genfit announced the discontinuation of the RESOLVE-IT Phase 3 clinical trial of elafibranor in adults with non-alcoholic steatohepatitis and fibrosis. On May 11, the company announced the results from the interim analysis of the RESOLVE-IT Phase 3 trial, which did not meet the predefined primary surrogate efficacy endpoint of NASH resolution without worsening of fibrosis in the ITT population of 1,070 patients. Following the detailed review of the full RESOLVE-IT interim efficacy dataset, Genfit "determined that the investment needed to continue the trial was not justified, as it was unlikely to provide results that would be sufficient to support elafibranor for registration in NASH in the USA and Europe." Genfit will now engage with the RESOLVE-IT investigators to expedite the trial termination process. The company will also meet with regulatory agencies "to share key learnings, including upcoming results from the second reading of liver biopsies that will help better understand inter- reader variability and its impact." Genfit added that it is "committed to finalizing this process, considering that insights gained from such a large international Phase 3 trial will provide valuable and beneficial information for the whole of the NASH community." This decision is the first step of the new corporate strategy and allows GENFIT to accelerate its cost-saving plan, and to focus its efforts on developing its two major programs: elafibranor development in PBC, and the commercial growth of NIS4 , for NASH diagnostics.

ShowHide Related Items >><<
GNFT Genfit
$5.40 /

-0.18 (-3.23%)

GNFT Genfit
$5.40 /

-0.18 (-3.23%)

06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
GNFT Genfit
$5.40 /

-0.18 (-3.23%)

GNFT Genfit
$5.40 /

-0.18 (-3.23%)

Hot Stocks
Gamida Cell names Michele Korfin Chief Operating and Chief Commercial Officer » 08:18
07/21/20
07/21
08:18
07/21/20
08:18
GMDA

Gamida Cell

$4.43 /

-0.05 (-1.12%)

Gamida Cell announced the…

Gamida Cell announced the appointment of Michele Korfin as chief operating and chief commercial officer. Gamida Cell said in a release, "Ms. Korfin brings over 20 years of experience in oncology, focused on business operations and commercialization of novel therapies. In this role, she will have oversight of manufacturing and commercialization as Gamida Cell advances its clinical development candidates: omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of bone marrow transplant, and GDA-201, an investigational, natural killer cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma. Prior to joining Gamida Cell, Ms. Korfin served as COO at TYME Technologies."

ShowHide Related Items >><<
GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

07/01/20
Fly Intel: Top five analyst initiations
06/30/20 Evercore ISI
Gamida Cell initiated with an Outperform at Evercore ISI
05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

  • 19
    May
GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 10:05
07/01/20
07/01
10:05
07/01/20
10:05
PZZA

Papa John's

$80.96 /

+1.52 (+1.91%)

, DKNG

DraftKings

$34.10 /

+0.83 (+2.49%)

, WSC

WillScot Mobile Mini

$12.93 /

+0.64 (+5.21%)

, GMDA

Gamida Cell

$4.70 /

+0.15 (+3.30%)

, IHG

InterContinental

$45.30 /

+0.95 (+2.14%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Papa John's (PZZA) initiated with an Outperform at Wedbush. 2. DraftKings (DKNG) initiated with an Overweight at Stephens. 3. WillScot (WSC) initiated with a Buy at Stifel. 4. Gamida Cell (GMDA) initiated with an Outperform at Evercore ISI. 5. InterContinental (IHG) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WSC WillScot Mobile Mini
$12.93 /

+0.64 (+5.21%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

IHG InterContinental
$45.30 /

+0.95 (+2.14%)

GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

07/01/20 Wedbush
Wedbush bullish on Papa John's, initiates with an Outperform
06/30/20 Wedbush
Papa John's initiated with an Outperform at Wedbush
06/29/20 BTIG
Papa John's price target raised to $95 from $85 at BTIG
06/26/20 Stephens
Papa John's price target raised to $94 from $83 at Stephens
DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

06/30/20 Stephens
Stephens starts DraftKings at Overweight amid U.S. gambling 'mega-trend'
06/30/20 Stephens
DraftKings initiated with an Overweight at Stephens
06/26/20
Fly Intel: Top five analyst initiations
06/25/20 Rosenblatt
DraftKings initiated with a Buy at Rosenblatt
WSC WillScot Mobile Mini
$12.93 /

+0.64 (+5.21%)

06/30/20 Stifel
WillScot initiated with a Buy at Stifel
05/28/20 BofA
WillScot resumed with a Buy at BofA
11/25/19 DA Davidson
WillScot price target raised to $23 from $20 at DA Davidson
09/26/19 Deutsche Bank
WillScot acquisition of Mobile Mini would be well received, says Deutsche Bank
GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

06/30/20 Evercore ISI
Gamida Cell initiated with an Outperform at Evercore ISI
05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
IHG InterContinental
$45.30 /

+0.95 (+2.14%)

07/01/20 Credit Suisse
InterContinental initiated with a Neutral at Credit Suisse
06/26/20 Peel Hunt
InterContinental initiated with a Buy at Peel Hunt
06/25/20 Jefferies
InterContinental downgraded to Hold from Buy at Jefferies
06/23/20 HSBC
InterContinental price target lowered to 4,400 GBp from 5,000 GBp at HSBC
WSC WillScot Mobile Mini
$12.93 /

+0.64 (+5.21%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

  • 19
    Jun
  • 19
    May
PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

IHG InterContinental
$45.30 /

+0.95 (+2.14%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

IHG InterContinental
$45.30 /

+0.95 (+2.14%)

GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

Initiation
Gamida Cell initiated with an Outperform at Evercore ISI » 16:29
06/30/20
06/30
16:29
06/30/20
16:29
GMDA

Gamida Cell

$4.55 /

+0.07 (+1.56%)

Evercore ISI analyst…

Evercore ISI analyst Jonathan Miller initiated coverage of Gamida Cell with an Outperform rating.

ShowHide Related Items >><<
GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

  • 19
    May
GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

Recommendations
Intercept selloff yesterday overdone, says B. Riley FBR » 08:45
06/30/20
06/30
08:45
06/30/20
08:45
ICPT

Intercept

$46.64 /

-30.92 (-39.87%)

, GNFT

Genfit

$5.58 /

+0.01 (+0.18%)

, CBAY

CymaBay

$3.57 /

-0.175 (-4.68%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani lowered the firm's price target on Intercept Pharmaceuticals (ICPT) to $97 from $158 and keeps a Buy rating on the shares. The selloff yesterday on the unexpected receipt of a Complete Response Letter for obeticholic acid is overdone, Mamtani tells investors in a research note. With a large share of the FDA's infrastructure diverted towards COVID-19 drug development, it is reasonable for the agency to take more time in gaining comfort with obeticholic acid's clinical profile as well as histology-based surrogate endpoint that has recently been "muddled" by Genfit's (GNFT) Phase III unusually high placebo response and CymaBay's (CBAY) Phase II study challenged by errors in biopsy reads, says the analyst. Mamtani's long-term view remains favorable on approvability of obeticholic acid in nonalcoholic steatohepatitis.

ShowHide Related Items >><<
ICPT Intercept
$46.64 /

-30.92 (-39.87%)

GNFT Genfit
$5.58 /

+0.01 (+0.18%)

CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

ICPT Intercept
$46.64 /

-30.92 (-39.87%)

06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
06/30/20 BMO Capital
Intercept downgraded to Market Perform from Outperform at BMO Capital
06/30/20 UBS
Intercept downgraded to Neutral from Buy at UBS
06/30/20 Credit Suisse
Intercept downgraded to Neutral from Outperform at Credit Suisse
GNFT Genfit
$5.58 /

+0.01 (+0.18%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
ICPT Intercept
$46.64 /

-30.92 (-39.87%)

CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

GNFT Genfit
$5.58 /

+0.01 (+0.18%)

ICPT Intercept
$46.64 /

-30.92 (-39.87%)

GNFT Genfit
$5.58 /

+0.01 (+0.18%)

CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.